Bortezomib-induced peripheral neurotoxicity: An update

Archives of Toxicology

Volumn 88, Issue 9, 2014, Pages 1669-1679

  Argyriou, Andreas A ^a,b   Cavaletti, Guido ^c   Bruna, Jordi ^d   Kyritsis, Athanasios P ^e   Kalofonos, Haralabos P ^b  

^a UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Bortezomib; Diagnosis; Incidence; Neurotoxicity; Pathogenesis; Peripheral neuropathy; Treatment

Indexed keywords

BORTEZOMIB; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM ION; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; UBIQUITIN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

BORTEZOMIB INDUCED PERIPHERAL NEUROPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG INDUCED DISEASE; ELECTROPHYSIOLOGY; HUMAN; MEDICATION COMPLIANCE; MICROTUBULE ASSEMBLY; MULTIPLE MYELOMA; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RISK FACTOR; SCIATIC NERVE; SPINAL GANGLION; ANIMAL; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG MONITORING; INCIDENCE; NEUROTOXICITY SYNDROMES; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; SEVERITY OF ILLNESS INDEX;

ANIMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; INCIDENCE; NEUROTOXICITY SYNDROMES; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEASOME INHIBITORS; PYRAZINES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84906224476     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1316-5     Document Type: Review

References (94)

1. Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5(5):417-421
2. Alé A, Bruna J, Navarro X, Udina E (2014) Neurotoxicity induced by antineoplastic proteasome inhibitors. Neurotoxicology. doi:10.1016/j.neuro. 2014.02.001
3. Argyriou AA, Polychronopoulos P, Koutras A et al (2006) Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 14(3):223-229 (Pubitemid 43247926)
4. Argyriou AA, Polychronopoulos P, Koutras A et al (2007) Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. Eur J Cancer Care (Engl) 16(3):231-237
5. Argyriou AA, Iconomou G, Kalofonos HP (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112(5):1593-1599
6. Argyriou AA, Zolota V, Kyriakopoulou O, Kalofonos HP (2010) Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents. J BUON 15(3):435-446
7. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82(1):51-77
8. Argyriou AA, Briani C, Cavaletti G et al (2013) Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hocanalysis of a prospective study. Eur J Neurol 20(5):788-794
9. Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP (2014) Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res 6:135-147
10. Avcu F, Ural AU, Cetin T, Nevruz O (2008) Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res 121(4):567-571 (Pubitemid 351174280)
11. Azoulay D, Vachapova V, Shihman B, Miler A, Karni A (2005) Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 167(1-2):215-218 (Pubitemid 41242305)
12. Azoulay D, Lavie D, Horowitz N et al (2014) Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma. Br J Haematol 164(3):454-456
13. Bedford L, Hay D, Devoy A et al (2008) Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 28(33):8189-8198
14. Bostock H, Cikurel K, Burke D (1998) Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 21(2):137-158 (Pubitemid 28079733)
15. Boyette-Davis JA, Cata JP, Zhang H, Driver LC, Wendelschafer-Crabb G, Kennedy WR, Dougherty PM (2011) Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. J Pain 12(9):1017-1024
16. Broyl A, Corthals SL, Jongen JL et al (2010) Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 11(11):1057-1065
17. Broyl A, Jongen JL, Sonneveld P (2012) General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma. Semin Hematol 49(3):249-257
18. Bruna J, Udina E, Alé A et al (2010) Neurophysiological, histological and immunohistochemical characterization of bortezomibinduced neuropathy in mice. Exp Neurol 223(2):599-608
19. Bruna J, Alé A, Velasco R, Jaramillo J, Navarro X, Udina E (2011) Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model. J Peripher Nerv Syst 16(3):199-212
20. Carozzi VA, Canta A, Oggioni N et al (2010) Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. Exp Neurol 226(2):301-309
21. Carozzi VA, Renn CL, Bardini M et al (2013) Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse. PLoS ONE 8(9):e72995
22. Casafont I, Berciano MT, Lafarga M (2010) Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox Res 17(2):167-178
23. Cata JP, Weng HR, Burton AW, Villareal H, Giralt S, Dougherty PM (2007) Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 8(4):296-306 (Pubitemid 46551871)
24. Cavaletti G, Gilardini A, Canta A et al (2007) Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 204(1):317-325 (Pubitemid 46330280)
25. Cavaletti G, Frigeni B, Lanzani F et al (2010) Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46(3):479-494
26. Cavaletti G, Alberti P, Marmiroli P (2011) Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 12(12):1551-1561
27. Cavaletti G, Cornblath DR, Merkies IS, CI-PeriNomS Group et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24(2):454-462
28. Cavo M, Tacchetti P, Patriarca F et al (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376:2075-2085
29. Cavo M, Pantani L, Petrucci MT et al (2012) Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 120:9-19
30. Chiorazzi A, Canta A, Meregalli C et al (2013) Antibody against tumor necrosis factor-alpha reduces bortezomib-induced allodynia in a rat model. Anticancer Res 33(12):5453-5459
31. Cho J, Kang D, Lee JY, Kim K, Kim SJ (2014) Impact of dose modification on intravenous Bortezomib-induced peripheral neuropathy in multiple myeloma patients. Support Care Cancer. doi:10.1007/s00520-014-2256-6
32. Coiffier B, Osmanov EA, Hong X et al (2011) Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 12(8):773-784
33. Corso A, Mangiacavalli S, Varettoni M, Pascutto C, Zappasodi P, Lazzarino M (2010) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk Res 234:471-474
34. Corthals SL, Kuiper R, Johnson DC et al (2011) Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica 96(11):1728-1732
35. Desterro JM, Rodriguez MS, Hay RT (2000) Regulation of transcription factors by protein degradation. Cell Mol Life Sci 57(8-9):1207-1219 (Pubitemid 30663478)
36. Dimopoulos MA, Mateos MV, Richardson PG et al (2011) Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib- melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 86:23-31
37. Dimopoulos M, Siegel DS, Lonial S et al (2013) Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 14:1129-1140
38. Favis R, Sun Y, van de Velde H et al (2011) Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics 21(3):121-129
39. Finley D (2009) Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem 78:477-513
40. Fujimura H, Altar CA, Chen R et al (2002) Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 87(4):728-734 (Pubitemid 34302963)
41. Garderet L, Iacobelli S, Moreau P et al (2012) Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 30:2475-2482
42. Han SE, Boland RA, Krishnan AV, Vucic S, Lin CS, Kiernan MC (2008) Changes in human sensory axonal excitability induced by an ischaemic insult. Clin Neurophysiol 119(9):2054-2063
43. Harousseau JL, Attal M, Avet-Loiseau H et al (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stemcell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28:4621-4629
44. Hjorth M, Hjertner Ø, Knudsen LM et al (2012) Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol 88:485-496
45. Jagannath S, Barlogie B, Berenson J et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165-172 (Pubitemid 39371809)
46. Jagannath S, Durie BG, Wolf J et al (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129:776-783 (Pubitemid 40904528)
47. Kiernan MC, Bostock H (2000) Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain 123(12):2542-2551
48. Kiernan MC, Burke D, Andersen KV, Bostock H (2000) Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 23(3):399-409 (Pubitemid 30126986)
49. Lafarga M, Berciano MT, Pena E et al (2002) Clastosome: a sub-type of nuclear body enriched in 19S and 20S proteasomes, ubiquitin, and protein substrates of proteasome. Mol Biol Cell 13(8):2771-2782
50. Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT (2005) Mitochondrial-mediated disregulation of Ca2 + is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 65(9):3828-3836 (Pubitemid 40616363)
51. Lanzani F, Mattavelli L, Frigeni B et al (2008) Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst 13(4):267-274
52. Mateos MV, Hernández JM, Hernández MT et al (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108:2165-2172
53. McConkey DJ, Zhu K (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Update 11(4-5):164-179
54. McNicol ED, Midbari A, Eisenberg E (2013) Opioids for neuropathic pain. Cochrane Database Syst Rev 8:CD006146
55. Mellqvist UH, Gimsing P, Hjertner O et al (2013) Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 121:4647-4654
56. Meregalli C, Canta A, Carozzi VA et al (2010) Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 14(4):343-350
57. Meregalli C, Ceresa C, Canta A et al (2012) CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. J Pain Res 5:151-167
58. Meregalli C, Chiorazzi A, Carozzi VA et al (2014) Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy. Cell Cycle 13(4):612-621
59. Mikhael JR, Belch AR, Prince HM et al (2009) High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 144:169-175
60. Morabito F, Gentile M, Mazzone C et al (2011) Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood 118:5759-5766
61. Moreau P, Pylypenko H, Grosicki S et al (2011a) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12:431-440
62. Moreau P, Avet-Loiseau H, Facon T et al (2011b) Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118:5752-5758
63. Nasu S, Misawa S, Nakaseko C et al (2014) Bortezomib-induced neuropathy: axonal membrane depolarization precedes development of neuropathy. Clin Neurophysiol 125(2):381-387
64. Nodera H, Spieker A, Sung M, Rutkove S (2011) Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy. Neurosci Lett 505(3):223-227
65. Orlowski RZ, Nagler A, Sonneveld P et al (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25:3892-3901 (Pubitemid 47477266)
66. Palanca A, Casafont I, Berciano MT, Lafarga M (2014) Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons. Cell Mol Life Sci 71(10):1961-1975
67. Palumbo A, Bringhen S, Rossi D et al (2010) Bortezomib-melphalan- prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28:5101-5109
68. Park SB, Goldstein D, Krishnan AV et al (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63(6):419-437
69. Piperdi B, Ling YH, Liebes L, Muggia F, Perez-Soler R (2011) Bortezomib: understanding the mechanism of action. Mol Cancer Ther 10(11):2029-2030
70. Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C, Fojo T (2008) Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 7(7):940-949 (Pubitemid 351573790)
71. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9(7):739-744 (Pubitemid 28394160)
72. Ravaglia S, Corso A, Piccolo G et al (2008) Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 119(11):2507-2512
73. Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609-2617 (Pubitemid 36741588)
74. Richardson PG, Sonneveld P, Schuster MW et al (2005) Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498
75. Richardson PG, Mitsiades C, Hideshima T, Anderson KC (2006a) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57:33-47 (Pubitemid 43261977)
76. Richardson PG, Briemberg H, Jagannath S et al (2006b) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113-3120 (Pubitemid 46638949)
77. Richardson PG, Xie W, Mitsiades C et al (2009a) Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 27(21):3518-3525
78. Richardson PG, Sonneveld P, Schuster MW et al (2009b) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 144:895-903
79. Roccaro AM, Vacca A, Ribatti D (2006) Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov 1(3):397-403
80. Rosiñol L, Oriol A, Teruel AI et al (2012) Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 120:1589-1596
81. San Miguel JF, Schlag R, Khuageva NK, VISTA Trial Investigators et al (2008a) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917
82. San Miguel JF, Richardson PG, Sonneveld P et al (2008b) Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 22:842-849 (Pubitemid 351552634)
83. Shen M, Schmitt S, Buac D, Dou QP (2013) Targeting the ubiquitin-proteasome system for cancer therapy. Exp Opin Ther Targets 17(9):1091-1108
84. Siau C, Bennett GJ (2006) Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg 102(5):1485-1490
85. Sioka C, Kyritsis AP (2009) Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 63(5):761-767
86. Smith EM, Pang H, Cirrincione C, Alliance for Clinical Trials in Oncology et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359-1367
87. Sonneveld P, Schmidt-Wolf IG, van der Holt B et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 30:2946-2955
88. Staff NP, Podratz JL, Grassner L et al (2013) Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology 39:124-131
89. Tsukaguchi M, Shibano M, Matsuura A, Mukai S (2013) The protective effects of lafutidine for bortezomib induced peripheral neuropathy. J Blood Med 4:81-85
90. Velasco R, Petit J, Clapés V, Verdú E, Navarro X, Bruna J (2010) Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst 15(1):17-25
91. von Mikecz A (2006) The nuclear ubiquitin-proteasome system. J Cell Sci 119(Pt 10):1977-1984
92. Waxman SG (2008) Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nat Clin Pract Neurol 4(3):159-169
93. Zangari M, Guerrero J, Cavallo F, Prasad HK, Esseltine D, Fink L (2008) Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica 93(6):953-954 (Pubitemid 351821742)
94. Zaroulis CK, Chairopoulos K, Sachanas SP et al (2014) Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score. Leuk Lymphoma. doi:10.3109/10428194.2013.873535